Cell and gene therapies are the leading innovation to treat severe diseases such as cancer, as well as rare diseases. At present several therapies are in the market globally such as Yescarta, Kymriah, Alofisel, MACI, Epicel, Zolgensma, Luxturna etc. Many other cell and gene therapy are also in the developing phase. As of June 2020, more than 750 trials of cell and gene therapies in almost 30,000 patients were underway. COVID-19 has caused significant disruption to the cell and gene therapy industry because of the complex manufacturing, delivery and funding model. Cell collection, supply shortages and administration of cell and gene therapies have also proved problematic during the COVID-19 pandemic. Research programs and preclinical activities have been affected as companies have to reduce the number of people working on-site to keep them safe and follow the government's advice.
MNG Tracker anticipated that numbers of clinical trials and regulatory approvals for cell and gene therapies are expected to rise over the years to come. The US FDA anticipates that by 2025 it will approve 10 to 20 cell and gene therapy products per year. It is expected that the global cell and gene therapy market will grow at a CAGR of over 23 percent during the forecasting year 2021-2028 and likely to cross US$ 21 Billion landmarks in 2028. Cell therapy is dominating the global cell and gene therapy market. In the context of therapeutic class, Rare Diseases and oncology hold the majority of the share in this marketplace. However, Yescarta and Kymriah will hold the majority of the market share in the global cell and gene therapy market.
MNG Tracker report titled "Global Cell and Gene Therapy Market by Type (Cell, Gene), by Therapeutic Class (Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology, Other), by Products (Yescarta, Kymriah, Alofisel, MACI, Epicel, Zolgensma, Invossa, Luxturna, Zynteglo, Others), by Regions (North America, Europe, Asia-Pacific, Latin America, Other), by Company (Novartis, Gilead Sciences, Bristol-Myers Squibb, JW Therapeutics, 4basebio AG, CRISPR Therapeutics)” provides an all-encompassing insight of cell and gene therapy industry.
The objective of this study is to analyze Global Cell and Gene Therapy market by two prospective - cell and gene therapy market and biopharmaceutical company’s initiatives. Under the market section, we identifying the market growth potentials and market value by types, therapeutic class, marketed products and regions, growth drivers, challenges; whereas in company section our objectives are: to find out the key companies latest initiatives, company clinical trials and sales revenue in this market place.
This 230 pages study report with 65 Figures & 1 Tables studies the Global Cell and Gene Therapy market from 8 view points:
Market and Forecast
Market Share and Forecast
By Types - Market & Forecast
By Therapeutic Class - Market & Forecast
By Products – Market & Forecast
By Regions - Market & Forecast
Cell and Gene Therapy - Growth Drivers & Challenges
Cell and Gene Therapy - Company Profiles (Company overview, latest initiatives, clinical trials, sales revenue)
Global Cell and Gene Therapy Market - By Types
Global Cell and Gene Therapy Market - By Therapeutic Class
Global Cell and Gene Therapy Market - By Marketed Products
Global Cell and Gene Therapy Market - By Regions
Rest of the World
Key Company Profile - Company overview, latest initiatives, clinical trials, sales revenue
MNG Tracker is a market research company which offer market research reports and database subscription service. Continuous tracking on latest changes in the industry and predict about the emerging needs, challenges and opportunities, is the essential needs for the growth of the business. MNG Tracker is exists for that. MNG Tracker is steadily monitored on the latest happening in the industries, companies and regulatory policies around the world. MNG Tracker is all about market, research and data. We know our clients; who they are, what they see and what they do. MNG Tracker team is fully dedicated to achieve their needs and expectation.